Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Gram-negative Bacterial Protein Secretion Systems01:17

Gram-negative Bacterial Protein Secretion Systems

Gram-negative bacteria utilize sophisticated protein secretion systems to transport proteins across their double-membrane envelope into the extracellular environment or host cells. Based on their mechanism of action, these systems are classified into one-step and two-step pathways.One-Step Secretion Systems (Types I, III, IV, and VI)One-step secretion systems bypass the periplasm entirely, forming a continuous channel that spans both the inner and outer membranes:Type I Secretion System (T1SS):...
Bacterial Phylum Proteobacteria01:26

Bacterial Phylum Proteobacteria

Proteobacteria, one of the largest and most diverse bacterial phyla, encompasses a wide range of Gram-negative bacteria distinguished by their outer membrane composed of lipopolysaccharides. These microorganisms exhibit various metabolic capabilities, including phototrophy, chemolithotrophy, and heterotrophy, and thrive in diverse environments from soil to aquatic systems and host-associated niches. The phylum is divided into six classes: Alphaproteobacteria, Betaproteobacteria,...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Understanding Early and Late Endpoints in Registrational Trials of Community-acquired Bacterial Pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2020
Same author

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2019
Same author

Widening the Overton Window-While Avoiding Defenestration.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2019
Same author

Clostridium difficile Infection-Daily Symptoms (CDI-DaySymsâ„¢) questionnaire: psychometric characteristics and responder thresholds.

Health and quality of life outcomes·2019
Same author

Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae.

The New England journal of medicine·2019
Same author

Elaboration of Consensus Clinical Endpoints to Evaluate Antimicrobial Treatment Efficacy in Future Hospital-acquired/Ventilator-associated Bacterial Pneumonia Clinical Trials.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2019
Same journal

Self-medication with antibiotics and knowledge and attitudes toward rational antibiotic use among women of reproductive age.

Expert review of anti-infective therapy·2026
Same journal

Complicated urinary tract infections: evolving definitions, clinical burden, and treatment landscape amid antimicrobial resistance.

Expert review of anti-infective therapy·2026
Same journal

The changing picture of community acquired urinary tract infections in the US: a daunting prospect.

Expert review of anti-infective therapy·2026
Same journal

Study of prescription-indication of antivirals for herpesviruses in a Colombian population: a cross-sectional study.

Expert review of anti-infective therapy·2026
Same journal

Effectiveness and safety of eravacycline-based regimens for resistant <i>Acinetobacter baumannii</i> infections: a systematic review and meta-analysis.

Expert review of anti-infective therapy·2026
Same journal

<i>Pneumocystis</i> pneumonia in non-HIV immunocompromised patients in 2026: evolving therapeutic standards.

Expert review of anti-infective therapy·2026
See all related articles

Related Experiment Video

Updated: Jul 7, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

What is in the pipeline for Gram-negative pathogens?

George H Talbot1

  • 1Cerexa, Inc., 1751 Harbor Bay Parkway, Alameda, CA 94502, USA. talbot@aya.yale.edu

Expert Review of Anti-Infective Therapy
|February 7, 2008
PubMed
Summary
This summary is machine-generated.

New antimicrobial drugs are urgently needed to combat resistant Gram-negative bacteria like Acinetobacter baumannii and Pseudomonas aeruginosa. Current drug development is insufficient to address these critical public health threats.

More Related Videos

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria
08:34

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria

Published on: February 23, 2021

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Related Experiment Videos

Last Updated: Jul 7, 2026

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
08:19

Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing

Published on: July 7, 2020

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria
08:34

MS2-Affinity Purification Coupled with RNA Sequencing in Gram-Positive Bacteria

Published on: February 23, 2021

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth
09:10

Synthesis of Masarimycin, a Small Molecule Inhibitor of Gram-Positive Bacterial Growth

Published on: January 7, 2022

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Emerging pathogens and rising antimicrobial resistance (AMR) pose significant global health risks.
  • Gram-negative bacteria, including Acinetobacter baumannii and Pseudomonas aeruginosa, are increasingly difficult to treat.
  • The current pipeline for new antimicrobials, especially against Gram-negative pathogens, is critically limited.

Purpose of the Study:

  • To highlight the urgent need for novel antimicrobial agents and strategies.
  • To emphasize the inadequacy of current therapeutic options against problematic Gram-negative bacteria.
  • To advocate for increased research and development in antimicrobial discovery.

Main Methods:

  • Literature review and analysis of the current antimicrobial pipeline.
  • Assessment of the threat posed by resistant Gram-negative pathogens.
  • Evaluation of the limitations of existing and near-term antimicrobial therapies.

Main Results:

  • Existing and emerging antimicrobial candidates offer limited improvement over current treatments.
  • There is a significant gap in effective treatments for infections caused by multidrug-resistant Gram-negative bacteria.
  • Novel mechanisms of action and innovative approaches are essential for future therapeutic success.

Conclusions:

  • A substantial unmet need exists for new classes of antimicrobials with novel mechanisms.
  • Urgent prioritization of research and development is required to combat antimicrobial resistance.
  • Failure to act will exacerbate the public health crisis posed by untreatable bacterial infections.